Cargando…

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A

Antihemophilic factor (recombinant) (rAHF; ADVATE(®); Baxalta US Inc., a Takeda company, Lexington, MA, USA) is indicated for the treatment and prevention of bleeding in patients with hemophilia A. We aimed to assess the safety and efficacy of standard prophylaxis versus on-demand treatment with rAH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yongqiang, Hu, Yu, Jin, Jie, Zhao, Xielan, Wang, Xuefeng, Wu, Runhui, Wu, Depei, Yang, Renchi, Yang, Feng’e, Hu, Qun, Wang, Juan, Fang, Hai, Engl, Werner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890741/ https://www.ncbi.nlm.nih.gov/pubmed/33587652 http://dx.doi.org/10.1177/1076029621989811

Ejemplares similares

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu, Runhui, et al.
Publicado: (2020)

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A
por: Rossbach, Hans-Christoph
Publicado: (2010)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
por: Yang, Renchi, et al.
Publicado: (2020)

Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
por: Pipe, Steven
Publicado: (2009)

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016)

Multidisciplinary Team Management of Severe Hemophilia A with Non-ST Elevation Myocardial Infarction
por: Peng, Jie, et al.
Publicado: (2021)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)
por: Konkle, Barbara A, et al.
Publicado: (2021)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital
por: Li, Peijing, et al.
Publicado: (2019)

Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation
por: Liu, Wei, et al.
Publicado: (2022)

New developments in the management of moderate-to-severe hemophilia B
por: Nazeef, Moniba, et al.
Publicado: (2016)

Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
por: Berntorp, Erik, et al.
Publicado: (2014)

Prediction of moderately severe and severe acute pancreatitis in pregnancy: Several issues
por: Yang, Qun-Ying, et al.
Publicado: (2022)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B
por: Windyga, Jerzy, et al.
Publicado: (2020)

Efficacy and Safety Analysis of Combination Therapy Consisting of Intravenous Immunoglobulin and Corticosteroids versus Respective Monotherapies in the Treatment of Relapsed ITP in Adults
por: Fang, Lijun, et al.
Publicado: (2023)

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, F., et al.
Publicado: (2022)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
por: You, Chur Woo, et al.
Publicado: (2019)

In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor
por: Colling, Meaghan E., et al.
Publicado: (2019)

P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, Feng, et al.
Publicado: (2023)

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
por: Xu, Qian, et al.
Publicado: (2023)

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China
por: Yang, Renchi, et al.
Publicado: (2021)

Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)
por: Ueda, Hitoshi, et al.
Publicado: (2020)

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study
por: Mahlangu, Johnny, et al.
Publicado: (2022)

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations
por: Li, Zekun, et al.
Publicado: (2020)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)

Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
por: Stidl, Reinhard, et al.
Publicado: (2018)

Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
por: Male, Christoph, et al.
Publicado: (2020)

Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate‐severe hemophilia A
por: Funk, Sharon M., et al.
Publicado: (2019)

Masculinity Challenges for Men With Severe Hemophilia
por: Reinicke, Kenneth, et al.
Publicado: (2019)

Analysis of hospitalization of people with hemophilia—12 years of experience in a single center
por: Qu, Cuiyun, et al.
Publicado: (2022)

T2 mapping in the quantitative evaluation of articular cartilage changes in children with hemophilia: A pilot study
por: Zhang, Ningning, et al.
Publicado: (2019)

Prevalence of non-Alcoholic Fatty Liver Disease and Associated Factors in Patients with Moderate or Severe Hemophilia: A Multicenter-Based Study
por: Shen, Ming-Ching, et al.
Publicado: (2022)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sob0p0o000fs3hg7pta4rt044i